Collaborators and Funders

The STAMPEDE2 trial is jointly funded by Cancer Research UK for Comparison S, Novartis/ADACAP for Comparison P, and Janssen Pharmaceutica NV for Comparison N (funding provided up to June 2024).

Please click on the links below to find out more about our collaborators and funders. 

Cancer Research UK

Cancer Research UK is the world’s largest independent cancer research organisation and charity, formed in 2002 by the merger of The Cancer Research Campaign and the Imperial Cancer Research Fund. It conducts research using its own staff and grant-funded researchers, provides information about cancer, and runs campaigns aimed at raising awareness. Its pioneering work into the prevention, diagnosis, and treatment of cancer has helped save millions of lives.

Johnson & Johnson

Janssen, Pharmaceutical Companies of Johnson & Johnson, based in over 150 countries, brings together the most creative minds and cutting-edge technology to help treat, cure, stop, and prevent some of the most complex diseases of our time. Janssen focuses on areas of medicine where it can make the biggest difference: Cardiovascular, Metabolism & Retina, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Funding was received from Johnson & Johnson in the trial set up phase.

Novartis / ADACAP

Advanced Accelerator Applications (ADACAP), a Novartis Company, focusses on reimagining nuclear medicine and cancer care. They are committed to transforming patients’ lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology.

Radiotherapy Trials Quality Assurance (RTTQA) Group

The Radiotherapy Trials Quality Assurance (RTTQA) group is an independent quality assurance network based across several UK NHS sites. Its primary role is to ensure the safety, consistency and accuracy of radiotherapy treatments undertaken within clinical trials. The STAMPEDE2 trial has been featured on the RTTQA website! The page regarding STAMPEDE2 contains a prostate SABR/CRT QA summary, and an oligomet SABR QA summary, both under Comparison S. Please find the webpage here:  STAMPEDE2 RTTQA Quality Assurance Summary